• Praeruptorin A Workflows for Inflammation Research

  2026-08-11

  Praeruptorin A is an angular pyranocoumarin compound suited to mechanism-led studies of ferroptosis, epithelial barrier injury, cardiomyopathy, and tumor invasion. This practical guide connects concentration selection, pathway readouts, dosing logistics, and troubleshooting to help researchers build reproducible preclinical workflows.

• Single-Molecule Screening of Fast-Dissociating Antibodies

  2026-08-11

  Miyoshi and colleagues developed a semi-automated single-molecule TIRF microscopy assay that identifies specific antibodies with rapid dissociation directly from hybridoma cultures. The resulting Fab probes supported multiplexed super-resolution imaging and revealed rapid espin turnover within the dense, long-lived actin cores of inner-ear stereocilia.

• Dacarbazine Workflows for Cancer Drug Response

  2026-08-10

  Build more informative Dacarbazine assays by separating growth inhibition from actual cell killing. This workflow combines DNA-damage profiling, endpoint-specific controls, and practical troubleshooting for malignant melanoma, Hodgkin lymphoma, and sarcoma models.

• Streptavidin-FITC for LNP Trafficking

  2026-08-09

  A mechanistic and translational perspective on using Streptavidin-FITC to track biotinylated cargo, interpret LNP trafficking, and improve fluorescence-based assay strategy.

• Gut Dysbiosis and Docetaxel Resistance in Prostate Cancer

  2026-08-08

  Zhong et al. connect antibiotic-associated gut dysbiosis with prostate cancer progression and reduced Docetaxel sensitivity through increased gut permeability, intratumoral lipopolysaccharide, and activation of the NF-κB–IL6–STAT3 axis. The study combines mouse models, fecal microbiota transplantation, 16S rRNA profiling, mechanistic assays, and patient samples to identify Proteobacteria enrichment as a candidate marker of advanced disease.

• Penicillin G Sodium: Applied Research Workflows

  2026-08-07

  Penicillin G Sodium is a natural penicillin antibiotic for controlled Gram-positive selection, infection-model benchmarking, and contamination management—not a universal cell-culture additive. This guide connects its bacterial cell wall mechanism with barrier-inflammation workflows while separating product-supported evidence from practical assay recommendations.

• Cy5 TSA Fluorescence System Kit: Signal Amplification in IHC

  2026-08-07

  The Cy5 TSA Fluorescence System Kit delivers robust, HRP-catalyzed tyramide deposition for 100-fold signal amplification in immunohistochemistry and in situ hybridization. This kit enables sensitive detection of low-abundance targets and reduces reagent consumption, with fast, covalent Cy5 labeling for high-resolution imaging.

• ST3GAL1-Mediated Sialylation Drives Fusobacterium Adhesion i

  2026-08-06

  This study identifies ST3GAL1-driven sialylation as a key mechanism enhancing the adhesion and colonization of Fusobacterium nucleatum in colorectal cancer cells. The findings deepen our understanding of host-microbe interactions in tumor microenvironments and highlight sialylated glycans as potential targets for investigating microbial persistence in cancer.

• Solving Assay Challenges with EZ Cap™ Cy5 Firefly Luciferase

  2026-08-06

  Discover how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) addresses persistent laboratory challenges in mRNA delivery, cell viability, and bioluminescence assays. This scenario-driven guide offers validated, evidence-based insights for optimizing workflow sensitivity and reliability using APExBIO’s advanced dual-reporter mRNA.

• Scenario-Driven Workflows with Bromodomain Inhibitor, (+)-JQ

  2026-08-05

  This article guides researchers through real laboratory challenges in apoptosis, viability, and inflammation assays, demonstrating how Bromodomain Inhibitor, (+)-JQ1 (SKU A1910) from APExBIO delivers data-backed, reproducible solutions. Each section addresses practical experimental bottlenecks, protocol optimization, and vendor reliability, offering scenario-based insights for biomedical scientists.

• Fludarabine as a DNA Synthesis Inhibitor: Redefining Immuno-

  2026-08-05

  Explore how Fludarabine, a potent DNA synthesis inhibitor, uniquely enables advanced immuno-oncology research. This article delves into assay design, mechanistic synergy with T cell therapies, and practical guidance for optimizing experimental outcomes.

• BIBP 3226 Trifluoroacetate: Workflow Advances in NPY/NPFF Re

  2026-08-04

  BIBP 3226 trifluoroacetate empowers precise dissection of neuropeptide Y and FF receptor pathways, driving innovation in anxiety, analgesia, and cardiovascular research. With robust protocol versatility and proven high-affinity antagonism, it stands as a cornerstone for reproducible NPY/NPFF system studies.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-08-04

  Schwartz's dissertation introduces a nuanced framework for evaluating anti-cancer drug responses, distinguishing between growth inhibition and cell death in vitro. This approach clarifies drug action profiles, crucial for optimizing antineoplastic chemotherapy drug development and translational cancer research.

• Npt1-Mediated Renal Transport of Faropenem Sodium: Mechanism

  2026-08-03

  This study elucidates how the inorganic phosphate transporter Npt1 mediates the renal secretion of faropenem sodium, a penem antibiotic, by demonstrating its substrate specificity and transport kinetics. These mechanistic insights inform antibiotic pharmacokinetics, resistance research, and experimental design in infection models.

• Praeruptorin A: Multipathway Leverage for Translational Impa

  2026-08-03

  Praeruptorin A, an angular pyranocoumarin compound from Peucedanum praeruptorum Dunn, is redefining the translational research landscape. By integrating mechanistic clarity—ranging from ferroptosis inhibition to STAT-1/3 and NF-κB modulation—with actionable protocol guidance, this article provides researchers with a strategic roadmap. It contextualizes recent evidence on Praeruptorin A's anti-inflammatory efficacy in ulcerative colitis, explores its value in cancer and cardiomyopathy models, and maps the competitive and translational implications for the next generation of disease-modifying research.

15194 records 1/1013 page Next 12345 下5页 Last page